Qualigenix provides sleep medicine billing services for sleep practices and sleep centers: study and interpretation coding, study prior authorization, home-versus-in-lab checks, PAP adherence tracking, and denial follow-up, delivered remotely to practices in 48 states. Medicare keeps paying for CPAP only when the follow-up visit and the patient's nightly usage records meet its rules. Qualigenix codes sleep studies and interpretations correctly and tracks each patient's adherence window so coverage doesn't lapse.
Sleep medicine billing requires the right study code for where the study happened, the right split between the technical and interpretation components, and the documentation payers need to keep paying for treatment. Under Medicare's PAP coverage rules, continued coverage needs a face-to-face visit between days 31 and 91 of therapy and download data showing use of 4 or more hours a night on 70% of nights in a 30-day period. Qualigenix tracks each of these for every patient.
In-lab studies, home sleep tests and daytime sleepiness tests each have their own codes. When the facility and the interpreting physician bill separately, each claim needs the right component modifier, or one of them goes unpaid.
Many plans require prior authorization for in-lab polysomnography, titration studies and repeat studies, often through a benefit manager. Studies run without approval are commonly denied.
Medicare's PAP coverage rule (LCD L33718) requires a face-to-face re-evaluation between day 31 and day 91 after therapy starts, plus objective adherence data. A visit outside that window, or without download data, can end the patient's PAP coverage.
Many payers require a home sleep test first and approve an in-lab study only for specific clinical reasons. Billing an in-lab study without documenting why a home test wasn't appropriate invites denial.
Benefit checks have to cover the payer's testing policy as well as eligibility. Practices that verify coverage only at scheduling often learn about a home-test-first rule after the study.
Coverage for PAP starts with a face-to-face evaluation before the study and a study result that meets the payer's apnea-hypopnea index threshold. Missing either record stops coverage before treatment begins.
The most common sleep denials are missing authorization, an in-lab study billed without a home test, missing adherence data and the wrong component billed. An authorization and component check before submission catches most of them.
Attended studies have supervision requirements, some payers require sleep facility accreditation, and physician self-referral rules limit how sleep physicians can supply PAP equipment.
Qualigenix follows each patient from the first order to continued PAP coverage.
Our coders bill each study with the right code and the TC, 26 or global component, based on who performed and who interpreted it. Qualigenix holds 98.9% coding accuracy across all specialties it codes.
We request authorizations for in-lab, titration and repeat studies and track each approval against the scheduled date.
We track each new PAP patient's day 31 to 91 window and flag when the follow-up visit and download data are due.
Place of service and telehealth modifiers are checked on every claim, so home, lab and virtual visits are billed correctly.
Eligibility, testing policies and authorization rules are checked before the study is ordered.
Studies and follow-up visits are checked against the payer's coverage criteria, including the face-to-face evaluation, study results and adherence data.
Component and authorization denials are corrected and resubmitted; medical necessity denials are appealed with study results and adherence data. Qualigenix overturns 79% of the denials it works.
Claims are checked against supervision requirements and self-referral limits on equipment before submission.
Claims go out with an under 24-hour average submission turnaround, payments are posted by study type and component, and unpaid claims are worked before they age. Reports show study volume and revenue by payer.
Sleep-study interpretations (95811-26) were billed without the professional-component modifier 26 at facility sites, so reads denied as duplicates of the global study, and PAP-compliance management went uncaptured.
We applied modifier 26 on facility reads, captured PAP-management and E/M services, and validated home vs in-lab oversight coding.
Interpretation and PAP-management claims aged after denials went unworked, leaving a backlog of sleep-management charges.
We reworked denials, captured PAP-compliance and oversight coding, and standardized submission.
Sleep studies and PAP devices proceeded before authorization, driving denials on studies and durable medical equipment.
We added authorization tracking for studies and PAP devices and verified coverage before service.
Attended polysomnography (95810) and polysomnography with PAP titration (95811).
Qualigenix bills sleep medicine within the rules that apply: the criteria in Medicare's PAP coverage policy (LCD L33718), the face-to-face evaluation before testing, supervision requirements for attended studies, accreditation where payers require it, and physician self-referral limits on PAP equipment. All work is HIPAA-compliant.

Sleep practices choose Qualigenix because it tracks each patient from the first study order to continued PAP coverage. Precision across that chain produces measured Progress in collections. Qualigenix results across all specialties it bills:
Qualigenix prices sleep medicine billing after reviewing your study volume, visit mix and payer mix. A free billing audit gives you a quote and shows where studies go unpaid. Call 786-259-0231 to start.
When the interpreting physician doesn't own the equipment, the physician bills the interpretation with modifier 26 and the facility bills the technical component with TC. When one entity does both, it bills the global code.
Yes. Qualigenix bills telehealth sleep visits with modifier 95 and the right place of service, under each payer's telehealth rules.
Yes. Qualigenix works unpaid and denied sleep study claims, corrects components and authorizations, and appeals where the record supports payment. Most practices start with a free AR review.
Many payers require a home sleep apnea test first and approve an in-lab study only when a home test isn't appropriate, such as with certain heart, lung or neuromuscular conditions. We check each payer's policy before the study is scheduled.
Medicare requires a face-to-face visit with the treating clinician between days 31 and 91 of therapy, documenting that symptoms improved, plus download data showing use of 4 or more hours a night on 70% of nights in a 30-day period.
Qualigenix works in 133 EMR and EHR platforms and bills from the systems your practice already uses. We confirm access and workflow during onboarding.